Analyzing Current Therapies for Well-Differentiated Grade 3 Neuroendocrine Tumors

Opinion
Video

Panelists discuss how treatment selection for well-differentiated grade 3 neuroendocrine tumors requires careful consideration of factors including Ki-67 index, tumor biology, and disease progression rate to determine whether platinum-based chemotherapy or targeted therapies are most appropriate.

Recent Videos
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content
FDA acceptance is based on phase 3 CABINET trial results, with cabozantinib showing a PFS improvement in patients with pancreatic neuroendocrine tumors.

FDA Accepts sNDA for Cabozantinib in Pancreatic Neuroendocrine Tumors

Roman Fabbricatore
August 8th 2024
Article

FDA acceptance is based on phase 3 CABINET trial results, with cabozantinib showing a PFS improvement in patients with pancreatic neuroendocrine tumors.

Data from 2 NETTER trials support lutetium Lu 177 dotatate's approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

FDA Approves Lutetium Lu 177 Dotatate in Pediatric SSTR+ GEP-NETs

Ariana Pelosci
April 23rd 2024
Article

Data from 2 NETTER trials support lutetium Lu 177 dotatate's approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.

BXCL701 Earns FDA FTD in Small Cell Neuroendocrine Prostate Cancer

Russ Conroy
February 12th 2024
Article

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.

Data from the phase 3 NETTER-2 trial support the frontline use of Lutetium Lu 77 dotatate well-differentiated gastroenteropancreatic neuroendocrine tumors.

Radioligand Therapy Significantly Improves PFS in GEP-NET Population

Ashling Wahner
January 20th 2024
Article

Data from the phase 3 NETTER-2 trial support the frontline use of Lutetium Lu 77 dotatate well-differentiated gastroenteropancreatic neuroendocrine tumors.

177Lu-PNT2003 is a generic version of lutetium Lu 177 dotatate, which is used to treat somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors.

FDA Accepts Abbreviated NDA for 177Lu-PNT2003 in SSTR+ GEP-NETs

Hayley Virgil
January 12th 2024
Article

177Lu-PNT2003 is a generic version of lutetium Lu 177 dotatate, which is used to treat somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors.

Cabozantinib may become a new treatment option for those with previously treated advanced neuroendocrine tumors based on data from the phase 3 CABINET trial.

Cabozantinib Improves PFS Vs Placebo in Advanced Neuroenocrine Tumors

Kyle Doherty
October 22nd 2023
Article

Cabozantinib may become a new treatment option for those with previously treated advanced neuroendocrine tumors based on data from the phase 3 CABINET trial.